Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial

Back in 2006, Novartis execs scooped up rights to Kyorin’s immunosuppressant drug program for KRP-203, an S1P drug that the pharma giant initially thought had some real potential.

But Mayzent (siponimod) ultimately stole the S1P show at Novartis, which would go on to win a first-in-class FDA OK in multiple sclerosis, with KRP-203 abandoned along the way still in early-stage development.

Until today.